|
Volumn 349, Issue 6244, 2015, Pages 139-140
|
The modern era of HIV-1 vaccine development: Current vaccine designs are on the path to eliciting antibodies that neutralize HIV-1
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CD4 ANTIGEN;
DISULFIDE;
GLYCOPROTEIN GP 120;
GLYCOPROTEIN GP 41;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
NEUTRALIZING ANTIBODY;
VIRUS ANTIBODY;
VIRUS ENVELOPE PROTEIN;
GLYCOPROTEIN GP 160;
HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;
MONOCLONAL ANTIBODY;
ANTIBODY;
HUMAN IMMUNODEFICIENCY VIRUS;
NEUTRALIZATION;
VACCINE;
ANTIBODY RESPONSE;
ARTICLE;
BINDING SITE;
DISULFIDE BOND;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
IMMUNOGLOBULIN VARIABLE REGION;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN ENGINEERING;
SOMATIC MUTATION;
VACCINATION;
ANIMAL;
HIV INFECTIONS;
HUMAN IMMUNODEFICIENCY VIRUS 1;
IMMUNOLOGY;
HUMAN IMMUNODEFICIENCY VIRUS 1;
AIDS VACCINES;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEUTRALIZING;
ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;
HIV ANTIBODIES;
HIV ENVELOPE PROTEIN GP120;
HIV ENVELOPE PROTEIN GP160;
HIV ENVELOPE PROTEIN GP41;
HIV INFECTIONS;
HIV-1;
HUMANS;
|
EID: 84937511644
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.aac7800 Document Type: Article |
Times cited : (30)
|
References (14)
|